Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin

Journal of Hepatology

Volumn 60, Issue 1, 2014, Pages 16-21

  Andriulli, Angelo ^a   Di Marco, Vito ^b   Margaglione, Maurizio ^c   Ippolito, Antonio Massimo ^a   Fattovich, Giovanna ^d   Smedile, Antonina ^e   Valvano, Maria Rosa ^a   Calvaruso, Vincenza ^b   Gioffreda, Domenica ^a   Milella, Michele ^f   Morisco, Filomena ^g   Felder, Martina ^h   Brancaccio, Giuseppina ⁱ   Fasano, Massimo ^c   Gatti, Pietro ^f   Tundo, Paolo ^j   Barone, Michele ^f   Cozzolongo, Raffaele ^k   Angelico, Mario ^l   D'Andrea, Giovanna ^c   Andriulli, Nicola ^m   Abate, Maria Lorena ^e   Mazzella, Giuseppe ⁿ   Gaeta, Giovanni Battista ⁱ   Craxi, Antonio ^b   Santantonio, Teresa ^c   more..

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h Central Hospital   (Italy)

ⁱ SECOND UNIVERSITY OF NAPLES   (Italy)

^j S Caterina Novella Hospital   (Italy)

^k NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^l UNIVERSITY OF ROME TOR VERGATA   (Italy)

^m SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁿ UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

Chronic HCV liver disease; HCV; Peg interferon; Predictors of response; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; INTERLEUKIN 28B; VIRUS RNA;

ADULT; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; FEMALE; FIBROSIS; GENOTYPE; GENOTYPE 1 HEPATITIS C VIRUS; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIREMIA; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; LIVER FIBROSIS; THROMBOCYTE COUNT;

CHRONIC HCV LIVER DISEASE; HCV; PEG-INTERFERON; PREDICTORS OF RESPONSE; RIBAVIRIN;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL;

EID: 84890558893     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.07.040     Document Type: Article

References (22)

1. I.M. Jacobson, J.G. McHutchison, and G. Dusheiko Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
2. F. Poordad, J. McCone, and B.R. Bacon Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 365 2011 1014 1024
3. M.G. Ghany, D.R. Nelson, and D.B. Strader An update on treatment of genotype 1 chronic C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
4. P. Ramachandran, A. Fraser, and K. Agarwal UK consensus guideline for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients Aliment Pharmacol Therap 35 2012 647 662
5. H.S. Yee, M.E. Ghang, and Ch. Pocha Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office Am J Gastroenterol 107 2012 669 689
6. S. Liu, L.E. Cipriano, M. Holodniy, D.K. Owens, and J.D. Goldhaber-Friebert New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis Ann Intern Med 156 2012 279 290
7. C. Cammà, S. Petta, and M. Enea Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C Hepatology 17 2012 823 831
8. M. Simin, J. Brok, D. Stimac, C. Gluud, and L.I. Gluud Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C Aliment Pharmacol Ther 25 2007 1153 1162
9. M.W. Fried, M.L. Shiffman, and K.R. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
10. M. Manns, J.G. McHutchison, and S.C. Gordon Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 2001 958 965
11. D. Ge, J. Fellay, and A.J. Thompson Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 17 2009 399 401
12. A. Andriulli, A. Iacobellis, and M.R. Valvano Estimates of HCV-1 patients attaining RVR following dual therapy with peg-interferon and ribavirin Dig Dis Sci 58 2013 1371 1382
13. P. Bedossa, and T. Poynard An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group Hepatology 24 1996 289 293
14. V. Symonosky The diagnosis of cirrhosis by high resolution ultrasound of the liver surface Br J Radiol 72 1999 29 34
15. A. Iacobellis, A. Mangia, and G. Leandro External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis Am J Gastroenterol 100 2005 868 873
16. L. Castera Non invasive method to assess liver disease in patients with hepatitis B and C Gastroenterology 142 2012 1293 1302
17. T. Poynard, V. de Ledinghen, and J.P. Zarski Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard J Hepatol 56 2012 541 548
18. S. Zeuzem, M. Rodriguez-Torres, and K.E. Reddy Optimized threshold foR serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterfern alfa-2a/ribavirin J Viral Hepat 19 2012 766 774
19. A.J. Thompson, A.J. Muir, and M.S. Sulkowski Interleukin28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 139 2010 120 129
20. V. Di Marco, L. Covolo, and V. Calvaruso Who is more likely to respond to dual treatment with PEG-Interferon and Ribavirin for chronic hepatitis C? A gender-oriented analysis J Viral Hepat 20 2013 113 121
21. V. Di Marco, V. Calvaruso, and S. Grimaudo Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices J Viral Hepat 20 2013 113 121
22. S. Zeuzem, M. Buti, and P. Ferenci Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia J Hepatol 44 2006 97 103